PL4103161T3 - Kompozycje i ich zastosowania - Google Patents
Kompozycje i ich zastosowaniaInfo
- Publication number
- PL4103161T3 PL4103161T3 PL21709784.9T PL21709784T PL4103161T3 PL 4103161 T3 PL4103161 T3 PL 4103161T3 PL 21709784 T PL21709784 T PL 21709784T PL 4103161 T3 PL4103161 T3 PL 4103161T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002926.0A GB202002926D0 (en) | 2020-02-28 | 2020-02-28 | Compositions and uses thereof |
| PCT/GB2021/050498 WO2021171035A1 (en) | 2020-02-28 | 2021-02-26 | Compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4103161T3 true PL4103161T3 (pl) | 2024-05-27 |
Family
ID=70278604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21709784.9T PL4103161T3 (pl) | 2020-02-28 | 2021-02-26 | Kompozycje i ich zastosowania |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230149385A1 (pl) |
| EP (1) | EP4103161B1 (pl) |
| JP (2) | JP7704768B2 (pl) |
| KR (1) | KR102804154B1 (pl) |
| CN (1) | CN115484938A (pl) |
| AU (1) | AU2021227457B2 (pl) |
| BR (1) | BR112022017110A2 (pl) |
| DK (1) | DK4103161T3 (pl) |
| ES (1) | ES2974772T3 (pl) |
| FI (1) | FI4103161T3 (pl) |
| GB (1) | GB202002926D0 (pl) |
| HR (1) | HRP20240236T1 (pl) |
| HU (1) | HUE066102T2 (pl) |
| LT (1) | LT4103161T (pl) |
| MX (1) | MX2022010561A (pl) |
| PL (1) | PL4103161T3 (pl) |
| PT (1) | PT4103161T (pl) |
| RS (1) | RS65259B1 (pl) |
| SI (1) | SI4103161T1 (pl) |
| SM (1) | SMT202400094T1 (pl) |
| WO (1) | WO2021171035A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202110990D0 (en) * | 2021-07-30 | 2021-09-15 | Benevolentai Cambridge Ltd | Organic compound and their uses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6930114B2 (en) * | 2000-12-13 | 2005-08-16 | Bayer Pharmaceuticals Corporation | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors |
| AU2005323794B2 (en) | 2005-01-07 | 2012-07-19 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| SG174810A1 (en) * | 2006-09-11 | 2011-10-28 | Matrix Lab Ltd | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| ME02337B (me) | 2009-02-05 | 2016-06-20 | Takeda Pharmaceuticals Co | Jedinjenja piridazinona |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| WO2012018059A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2014122161A (ja) | 2011-03-31 | 2014-07-03 | Astellas Pharma Inc | ピラゾール化合物 |
| JP6153513B2 (ja) | 2011-08-22 | 2017-06-28 | 武田薬品工業株式会社 | 哺乳類中のホスホジエステラーゼ（ｐｄｅ１０ａ）を定量的に画像化する放射性トレーサとしての放射標識された化合物及びその用途 |
| US9138494B2 (en) | 2011-12-23 | 2015-09-22 | Abbvie Inc. | Radiolabeled PDE10A ligands |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| EA034956B1 (ru) | 2014-09-29 | 2020-04-10 | Эа Фарма Ко., Лтд. | Способ для лечения язвенного колита |
| CA3049161C (en) * | 2016-11-24 | 2023-03-07 | Tianjin Hemay Bio-Tech Co., Ltd | Piperidine-2,6-dione derivatives and crohn's disease treating |
| WO2019079647A2 (en) * | 2017-10-18 | 2019-04-25 | Wuxi Nextcode Genomics Usa, Inc. | IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES |
-
2020
- 2020-02-28 GB GBGB2002926.0A patent/GB202002926D0/en not_active Ceased
-
2021
- 2021-02-26 AU AU2021227457A patent/AU2021227457B2/en active Active
- 2021-02-26 HU HUE21709784A patent/HUE066102T2/hu unknown
- 2021-02-26 ES ES21709784T patent/ES2974772T3/es active Active
- 2021-02-26 SM SM20240094T patent/SMT202400094T1/it unknown
- 2021-02-26 BR BR112022017110A patent/BR112022017110A2/pt unknown
- 2021-02-26 MX MX2022010561A patent/MX2022010561A/es unknown
- 2021-02-26 WO PCT/GB2021/050498 patent/WO2021171035A1/en not_active Ceased
- 2021-02-26 PT PT217097849T patent/PT4103161T/pt unknown
- 2021-02-26 DK DK21709784.9T patent/DK4103161T3/da active
- 2021-02-26 CN CN202180031469.XA patent/CN115484938A/zh active Pending
- 2021-02-26 KR KR1020227033569A patent/KR102804154B1/ko active Active
- 2021-02-26 US US17/802,949 patent/US20230149385A1/en not_active Abandoned
- 2021-02-26 JP JP2022551009A patent/JP7704768B2/ja active Active
- 2021-02-26 SI SI202130115T patent/SI4103161T1/sl unknown
- 2021-02-26 EP EP21709784.9A patent/EP4103161B1/en active Active
- 2021-02-26 HR HRP20240236TT patent/HRP20240236T1/hr unknown
- 2021-02-26 PL PL21709784.9T patent/PL4103161T3/pl unknown
- 2021-02-26 FI FIEP21709784.9T patent/FI4103161T3/fi active
- 2021-02-26 RS RS20240256A patent/RS65259B1/sr unknown
- 2021-02-26 LT LTEPPCT/GB2021/050498T patent/LT4103161T/lt unknown
-
2025
- 2025-02-06 JP JP2025018596A patent/JP2025081381A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK4103161T3 (da) | 2024-03-11 |
| AU2021227457A1 (en) | 2022-10-20 |
| HRP20240236T1 (hr) | 2024-04-26 |
| WO2021171035A1 (en) | 2021-09-02 |
| SMT202400094T1 (it) | 2024-05-14 |
| KR20220154133A (ko) | 2022-11-21 |
| CA3169489A1 (en) | 2021-09-02 |
| EP4103161B1 (en) | 2023-12-20 |
| FI4103161T3 (fi) | 2024-02-29 |
| EP4103161A1 (en) | 2022-12-21 |
| RS65259B1 (sr) | 2024-03-29 |
| AU2021227457B2 (en) | 2024-05-30 |
| SI4103161T1 (sl) | 2024-05-31 |
| LT4103161T (lt) | 2024-03-12 |
| CN115484938A (zh) | 2022-12-16 |
| BR112022017110A2 (pt) | 2022-11-16 |
| HUE066102T2 (hu) | 2024-07-28 |
| US20230149385A1 (en) | 2023-05-18 |
| KR102804154B1 (ko) | 2025-05-09 |
| PT4103161T (pt) | 2024-03-11 |
| JP7704768B2 (ja) | 2025-07-08 |
| JP2025081381A (ja) | 2025-05-27 |
| ES2974772T3 (es) | 2024-07-01 |
| MX2022010561A (es) | 2022-11-30 |
| GB202002926D0 (en) | 2020-04-15 |
| JP2023515551A (ja) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202001906D0 (en) | Compositions And Applications Thereof | |
| GB202411091D0 (en) | Compositions and uses | |
| GB202215065D0 (en) | Compositions and uses thereof | |
| PL4103161T3 (pl) | Kompozycje i ich zastosowania | |
| GB202209335D0 (en) | Compositions and uses thereof | |
| PL4168523T3 (pl) | Kompozycje i ich zastosowanie | |
| GB202111289D0 (en) | Compositions and uses thereof | |
| GB202110657D0 (en) | Compositions and uses thereof | |
| GB202107615D0 (en) | Compositions and uses thereof | |
| GB202107614D0 (en) | Compositions and uses thereof | |
| GB202107399D0 (en) | Compositions and uses thereof | |
| GB202105108D0 (en) | Compositions and uses thereof | |
| GB202018414D0 (en) | Compositions and uses thereof | |
| GB202016492D0 (en) | Compositions and uses thereof | |
| GB202016490D0 (en) | Compositions and uses thereof | |
| GB202012123D0 (en) | Compositions and uses thereof | |
| GB202011443D0 (en) | Compositions and uses thereof | |
| GB202009268D0 (en) | Compositions and uses thereof | |
| GB202007850D0 (en) | Compositions and uses thereof | |
| GB202007851D0 (en) | Compositions and uses thereof | |
| GB202007753D0 (en) | Compositions and uses thereof | |
| GB202006437D0 (en) | Compositions and uses thereof | |
| GB202006436D0 (en) | Compositions and uses thereof | |
| GB202005143D0 (en) | Compositions and uses thereof | |
| GB202114798D0 (en) | New uses and compositions |